Get the Stockscreener App
5.93
4.77%
0.27
Solid Biosciences Inc stock is traded at $5.93, with a volume of 794.41K.
It is up +4.77% in the last 24 hours and down -4.82% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.66
Open:
$5.73
24h Volume:
794.41K
Relative Volume:
0.51
Market Cap:
$461.76M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.9507
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
-2.95%
1M Performance:
-4.82%
6M Performance:
+2.60%
1Y Performance:
-37.18%
1-Day Range:
$5.655
$6.07
1-Week Range:
$5.4617
$6.28
52-Week Range:
$2.41
$10.07
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.93 | 469.55M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
What institutions are buying Solid Biosciences Inc. stock nowJuly 2025 Catalysts & High Accuracy Buy Signal Tips - beatles.ru
Solid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street Zen - MarketBeat
Solid Biosciences Inc. Stages Intraday Comeback — Trend ChangeQuarterly Profit Review & Weekly Market Pulse Updates - sundaytimes.kr
Is Solid Biosciences Inc. stock a value trapAnalyst Upgrade & Long Hold Capital Preservation Tips - mustnews.co.kr
Wyckoff Accumulation Phase Possible in Solid Biosciences Inc.2025 Valuation Update & Expert Curated Trade Setups - metal.it
Is Solid Biosciences Inc. stock a good pick for beginnersJuly 2025 Market Mood & Weekly Return Optimization Alerts - thegnnews.com
Why Solid Biosciences Inc. stock attracts strong analyst attentionJuly 2025 Spike Watch & Fast Entry High Yield Stock Tips - beatles.ru
Is now the right time to enter Solid Biosciences Inc.Market Growth Summary & AI Powered Trade Plan Recommendations - sundaytimes.kr
Solid Biosciences Reports Increased Assets Amid Ongoing Losses - MSN
Solid Biosciences Inc. shares fall 1.05% intraday as Tyra Biosciences reports financial results and clinical progress. - AInvest
Solid Biosciences Gains Momentum with Promising DMD Program and Strategic Expansion - TipRanks
Solid Biosciences’ SWOT analysis: promising DMD gene therapy stock faces pivotal year - Investing.com
Citi Maintains Buy Rating on Solid Biosciences with $16 Price Target - AInvest
Citizens JMP Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
J.P. Morgan Sticks to Their Buy Rating for Solid Biosciences (SLDB) - The Globe and Mail
SLDB’s Stock Market Adventure: -9.49% YTD Growth Amidst Volatility - investchronicle.com
JMP reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Can Solid Biosciences Inc. recover in the next quarter2025 Growth vs Value & Weekly Market Pulse Updates - Newser
40,930 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Purchased by XTX Topco Ltd - Defense World
Solid Biosciences (NASDAQ:SLDB) Shares Up 9.9% Following Strong Earnings - Defense World
Smart tools for monitoring Solid Biosciences Inc.’s price actionWeekly Volume Report & Weekly High Conviction Ideas - Newser
Is Solid Biosciences Inc. stock overhyped or has real potentialOptions Play & Real-Time Market Sentiment Alerts - Newser
Developing predictive dashboards with Solid Biosciences Inc. data2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Wedbush Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $14 - 富途牛牛
William Blair Maintains Buy Rating for Solid Biosciences, Raises Price Target to $15.44. - AInvest
A Quick Look at Today's Ratings for Solid Biosciences(SLDB.US), With a Forecast Between $10 to $20 - 富途牛牛
Solid Biosciences: Promising Developments and Financial Stability Drive Buy Rating - TipRanks
Solid Biosciences Raises up to $50 Million in Series C Financing - Bain Capital
How Solid Biosciences Inc. stock performs during market volatilitySecure Entry Point Finder with Analysis - Newser
Solid Biosciences shares rise 2.81% after-hours following Anixa Biosciences' patent extension to 2045. - AInvest
SOLID BIOSCIENCES Earnings Results: $SLDB Reports Quarterly Earnings - Quiver Quantitative
Solid Biosciences Pushes Forward Despite Growing Losses - Finimize
Solid Biosciences reports Q2 EPS (42c), consensus (49c) - TipRanks
Solid Biosciences Q2 net loss widens to $39.5 mln - MarketScreener
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences Inc. Reports Progress in Clinical Trials and Financial Highlights for Q2 2025 - Quiver Quantitative
How to read the order book for Solid Biosciences Inc.Market Forecast Summary Over Multi-Year Period - Newser
Applying big data sentiment scoring on Solid Biosciences Inc.Momentum Prediction Based on AI Backtesting - Newser
Risk adjusted return profile for Solid Biosciences Inc. analyzedStock Market Watch with Smart Filters - Newser
Solid Biosciences Inc. stock trend forecastFree Earnings Play Trade Plan With Alerts - Newser
Key resistance and support levels for Solid Biosciences Inc.Volume Confirmed Setup with Entry Confidence - Newser
Solid Biosciences (SLDB) Projected to Post Quarterly Earnings on Tuesday - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Solid Biosciences SLDB 2025Q2 Earnings Preview Upside Potential on Strategic Developments - AInvest
Will Solid Biosciences Inc. rebound enough to break evenPrice Movement and Market Sentiment Analysis - Newser
Applying Elliott Wave Theory to Solid Biosciences Inc.Chart Pattern Recognition for Profit Timing - Newser
Solid Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
How hedge fund analytics apply to Solid Biosciences Inc. stockSwing Entry Risk Mitigation with Chart Analysis - Newser
Allianz Asset Management GmbH Purchases Shares of 27,100 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Inc. shares rise 1.03% after-hours following Wall Street's recovery from jobs report-fueled losses. - AInvest
What is the dividend policy of Solid Biosciences Inc. stockGet timely alerts on market opportunities - Jammu Links News
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Solid Biosciences Inc Stock (SLDB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):